Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined ...

Medipost transitioned from cord blood banking to developing stem cell therapies, focusing on knee osteoarthritis and other ...

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

President Trump published letters to 17 major pharma companies reiterating his requirements for them to fulfill his MFN order ...